Mary E. Wadlinger

This profile gathers the share dealings of Mary E. Wadlinger in Forma Therapeutics Holdings, Inc., where the filings describe the role as chief executive. We count 7 filings; the first trade dates from 23 June 2020 and the latest from 23 February 2022.

Market trades split into 1 purchase and 4 sales (€40k). The amount is not disclosed for 4 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 2 share grants. 2022 to date brings no purchases and 1 sale.

The newest entry dates from 25 February 2022: an open-market sale of €40k, in Forma Therapeutics Holdings, Inc. The clock since the last published purchase (24 June 2020) now reads 2,329 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.